PCL Semaglutide 10mg

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its effects on body weight and cardiometabolic parameters in controlled research settings. In multiple studies utilizing once-weekly subcutaneous administration at a 2.4 mg dose, semaglutide consistently induced substantial reductions in body weight under experimental conditions. For example, in the STEP 5 investigation, which spanned 104 weeks, semaglutide treated subjects exhibited a mean body weight reduction of 15.2%, compared to 2.6% in control groups (Garvey et al., 2022). Similar effects were observed in the STEP 1 and STEP 3 trials, where mean body weight reductions of 14.9% and 16.0%, respectively, were reported after 68 weeks of semaglutide administration (Bergmann et al., 2023).

Semaglutide has also been associated with changes in cardiovascular endpoints in long duration studies. In a research protocol spanning a mean of 39.8 months and involving subjects with preexisting cardiovascular conditions and elevated body mass, semaglutide 2.4 mg administered weekly was associated with a reduced incidence of composite cardiovascular outcomes, including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke (Lincoff et al., 2023). An earlier trial using 0.5 mg and 1.0 mg doses similarly reported a statistically significant reduction in the rate of first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in subjects with type 2 diabetes treated with semaglutide relative to placebo (Marso et al., 2016).